Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept for kidney function preservation in high renal risk heart transplant recipients
2019-001510-42Phase 2Active
- Sponsor
- CHU de Nantes
- Start
- Jul 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of belatacept in heart transplantation and chronic kidney disease (CKD), sponsored by CHU de Nantes. Primary endpoint: Change in estimated glomerular filtration rate (eGFR) by CKD-EPI. Started Jul 2019; status: active.
02
Drugs
belatacept
03
Conditions
heart transplantationchronic kidney disease (CKD)
Beyond the preview
Go deeper on 2019-001510-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001510-42.